COMBINATION IRREVERSIBLE ELECTROPORATION AND ANTI-PD1 THERAPY REVERSES MDSC INDUCED IMMUNE-SUPPRESSIVE MICROENVIRONMENT IN HEPATOCELLULAR CARCINOMA.

被引：0
|
作者：
Huo, Jihui
Lei, Kai
Peng, Sui
Kuang, Ming
Dai, Zihao
Wang, Lina
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1550
引用
收藏
页码：S1725 / S1725
页数：1
相关论文
共 50 条
  • [1] Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
    Haber, Philipp K.
    Torres-Martin, Miguel
    Dufour, Jean-Francois
    Verslype, Chris
    Marquardt, Jens
    Galle, Peter R.
    Vogel, Arndt
    Meyer, Tim
    Labgaa, Ismail
    Roberts, Lewis R.
    Minguez, Beatriz
    Mazzaferro, Vincenzo
    Finkelmeier, Fabian
    Muller, Tobias
    Schmelzle, Moritz
    Finn, Richard S.
    Thung, Swan
    Villanueva, Augusto
    Sia, Daniela
    Llovet, Josep M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Molecular markers of response to anti-pd1 therapy in advanced hepatocellular carcinoma
    Haber, Philipp
    Torres-Martin, Miguel
    Andreu-Oller, Carmen
    Puigvehi, Marc
    Maeda, Miho
    Castet, Florian
    Radu, Pompilia
    Dufour, Jean-Francois
    Verslype, Chris
    Czauderna, Carolin
    Marquardt, Jens U.
    Galle, Peter
    Vogel, Arndt
    Bathon, Melanie
    Meyer, Tim
    Labgaa, Ismail
    Digkilia, Antonia
    Roberts, Lewis
    Ali, Mohamed A. Mohamed
    Minguez, Beatriz
    Citterio, Davide
    Mazzaferro, Vincenzo
    Finkelmeier, Fabian
    Trojan, Joerg
    Oezdirik, Burcin
    Mueller, Tobias
    Schmelzle, Moritz
    Bejjani, Anthony
    Finn, Richard
    Thung, Swan N.
    Villanueva, Augusto
    Sia, Daniela
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2021, 75 : S521 - S522
  • [3] Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma
    Haber, Philipp K.
    Castet, Florian
    Torres-Martin, Miguel
    Andreu-Oller, Carmen
    Puigvehi, Marc
    Miho, Maeda
    Radu, Pompilia
    Dufour, Jean-Francois
    Verslype, Chris
    Zimpel, Carolin
    Marquardt, Jens U.
    Galle, Peter R.
    Vogel, Arndt
    Bathon, Melanie
    Meyer, Tim
    Labgaa, Ismail
    Digklia, Antonia
    Roberts, Lewis R.
    Ali, Mohamed A. Mohamed
    Minguez, Beatriz
    Citterio, Davide
    Mazzaferro, Vincenzo
    Finkelmeier, Fabian
    Trojan, Joerg
    Ozdirik, Burcin
    Mueller, Tobias
    Schmelzle, Moritz
    Bejjani, Anthony
    Sung, Max W.
    Schwartz, Myron E.
    Finn, Richard S.
    Thung, Swan
    Villanueva, Augusto
    Sia, Daniela
    Llovet, Josep M.
    GASTROENTEROLOGY, 2023, 164 (01) : 72 - 88.e18
  • [4] Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
    Feng, Duan
    Hui, Xie
    Shi-Chun, Lu
    Yan-Hua, Bai
    Li, Cui
    Xiao-Hui, Li
    Jie-Yu, Yan
    ONCOTARGET, 2017, 8 (57) : 96649 - 96655
  • [5] MOLECULAR MARKERS OF RESPONSE TO ANTI-PD1 THERAPY IN ADVANCED HEPATOCELLULAR CARCINOMA
    Haber, Philipp K.
    Castet, Florian
    Torres-Martin, Miguel
    Andreu-Oller, Carmen
    Puigvehi, Marc
    Maeda, Miho
    Radu, Pompilia
    Dufour, Jean-Francois
    Verslype, Chris
    Czauderna, Carolin
    Marquardt, Jens U.
    Galle, Peter R.
    Vogel, Arndt
    Bathon, Melanie
    Meyer, Timothy
    Labgaa, Ismail
    Digklia, Antonia
    Roberts, Lewis R.
    Ali, Mohamed Mohamed
    Minguez, Beatriz
    Citterio, Davide
    Mazzaferro, Vincenzo
    Finkelmeier, Fabian
    Trojan, Jorg
    Ozdirik, Burcin
    Mueller, Tobias
    Schmelzle, Moritz
    Bejjani, Anthony
    Sung, Max W.
    Schwartz, Myron E.
    Finn, Richard
    Thung, Swan N.
    Villanueva, Augusto
    Sia, Daniela
    Llovet, Josep M.
    HEPATOLOGY, 2021, 74 : 109A - 110A
  • [6] HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
    Salman, Shaima
    Meyers, David J.
    Wicks, Elizabeth E.
    Lee, Sophia N.
    Datan, Emmanuel
    Thomas, Aline M.
    Anders, Nicole M.
    Hwang, Yousang
    Lyu, Yajing
    Yang, Yongkang
    Jackson, Walter, III
    Dordai, Dominic
    Rudek, Michelle A.
    Semenza, Gregg L.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (09):
  • [7] Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Pique-Gili, Marta
    Peix, Judit
    Montironi, Carla
    Abril-Fornaguera, Jordi
    Torrens, Laura
    Pinyol, Roser
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2020, 73 : S40 - S40
  • [8] Decision tree model with tumor immune function genes for predicting response to anti-PD1 therapy in renal cell carcinoma.
    Bi, Xingang
    Luo, Zhiwen
    Bi, Xinyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Clinical, pathologic, and genomic profiles of exceptional responders to anti-PD1 therapy in renal cell carcinoma.
    Ball, Mark Wayne
    Johnson, Michael Hiroshi
    Gorin, Michael A.
    Rodriguez, Maria
    Diaz, Luis A.
    Haffner, Michael
    Netto, George J.
    Drake, Charles G.
    Allaf, Mohamad E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [10] Comparison of anti-PD-L1 with anti-PD-1 antibodies in the combination of HAIC and lenvatinib for the treatment of unresectable hepatocellular carcinoma.
    Li, Shaohua
    Mei, Jie
    Wang, Qiaoxuan
    Zhao, Rongce
    Lu, Lianghe
    Deng, Min
    Lin, Wenping
    Guan, Renguo
    Wen, Yuhua
    Zheng, Lie
    Wei, Wei
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 509 - 509
12345